Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (2451)	1/3/2001 8:41:42 PM
From: scaram(o)uche	Respond to of 52153

It's the collective wisdom thing again. Ticks me off. The sector starts with a "b", sell the stock. Don't do any research to find out if it's over-valued, under-valued, fairly-valued, a steal, etc. The collective wisdom dictates that it should be sold.

To: tom pope who wrote (2451)	1/3/2001 10:00:58 PM
From: Scott H. Davis	Read Replies (1) \| Respond to of 52153

ABGX was especially strange. Down over 20% the last 2 days, yet the three news items together should have had a positive effect on price on a "sane" 2 day span. Abgenix Receives Additional Patent Grant for XenoMouse(TM) Technology biz.yahoo.com Abgenix to Proceed With Phase IIb Study of ABX-IL8 in Psoriasis. Primary Objectives Met in Preliminary Analysis of Phase IIa Study biz.yahoo.com Lexicon Genetics and Abgenix Enter Drug Target Validation Collaboration. Second Agreement to Advance Abgenix's Drug Discovery Efforts biz.yahoo.com